PPA
ABCL icon

Parametric Portfolio Associates’s AbCellera Biologics ABCL Stock Holding History

Parametric Portfolio Associates’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,000
Closed -$1.59M – 3598
2021
Q2 		$1.59M Buy
+11,000
New +$303K ﹤0.01% 2553

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return

Parametric Portfolio Associates's ABCL Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its AbCellera Biologics (ABCL) stake by 43% in Q1 2022, selling an estimated $8.05M and leaving 1,150,000 shares worth $11.2M. The position accounts for 0.01% of the portfolio, ranked #1287.

Parametric Portfolio Associates first reported a position in ABCL in Q2 2021 and has held it in 4 quarters since. The position peaked at $34.1M in Q3 2021. 130 funds tracked by Wall St. Rank hold ABCL as of Q1 2022.

  • Parametric Portfolio Associates held 1,150,000 shares of AbCellera Biologics worth $11.2M as of Q1 2022.
  • Parametric Portfolio Associates sold 850,000 AbCellera Biologics shares in Q1 2022, an estimated $8.05M.
  • AbCellera Biologics made up 0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1287 holding.
  • Parametric Portfolio Associates first reported a position in AbCellera Biologics in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's AbCellera Biologics position peaked at $34.1M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.